CY1105216T1 - Συστημα μικροβιακης παροχης - Google Patents

Συστημα μικροβιακης παροχης

Info

Publication number
CY1105216T1
CY1105216T1 CY20061100732T CY061100732T CY1105216T1 CY 1105216 T1 CY1105216 T1 CY 1105216T1 CY 20061100732 T CY20061100732 T CY 20061100732T CY 061100732 T CY061100732 T CY 061100732T CY 1105216 T1 CY1105216 T1 CY 1105216T1
Authority
CY
Cyprus
Prior art keywords
proteins
allergens
allergic reactions
subjects
allergic
Prior art date
Application number
CY20061100732T
Other languages
English (en)
Inventor
Michael Caplan
Original Assignee
Seer Pharmaceuticals, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seer Pharmaceuticals, Llc. filed Critical Seer Pharmaceuticals, Llc.
Publication of CY1105216T1 publication Critical patent/CY1105216T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους και συνθέσεις για τη θεραπεία ή πρόληψη αλλεργικών αντιδράσεων, ειδικότερα αναφυλακτικών αλλεργικών αντιδράσεων, σε υποκείμενα τα οποία είναι αλλεργικά σε αλλεργιογόνα ή επιρρεπή σε αλλεργίες. Οι μέθοδοι της παρούσας εφεύρεσης χρησιμοποιούν χορήγηση μικροοργανισμών σε υποκείμενα, όπου οι μικροοργανισμοί παράγουν αλλεργιογόνα και προστατεύουν τα υποκείμενα από έκθεση στα αλλεργιογόνα μέχρι να υποβληθούν σε φαγοκύτωση από τα κύτταρα που εμφανίζουν αντιγόνα. Ιδιαίτερα προτιμώμενοι μικροοργανισμοί είναι αρνητικά κατά gram βακτήρια, θετικά κατά gram βακτήρια, και ζυμομύκητες. Ιδιαίτερα προτιμώμενα αλλεργιογόνα είναι πρωτεΐνες που βρίσκονται σε τρόφιμα, δηλητήρια, φάρμακα και λάτεξ τα οποία προκαλούν αλλεργικές αντιδράσεις και αναφυλακτικές αλλεργικές αντιδράσεις σε πρόσωπα τα οποία είναι αλλεργικά στις πρωτεΐνες ή είναι επιρρεπή σε αλλεργίες στις πρωτεΐνες. Οι πρωτεΐνες μπορούν επίσης να είναι τροποποιημένες ώστε να περιορίζουν την ικανότητα των πρωτεϊνών να δεσμεύονται και να διασταυρώνονται με IgE αντισώματα και κατά συνέπεια περιορίζουν τον κίνδυνο πρόκλησης αναφυλαξίας χωρίς να προκαλούν ανοσία τύπου Th1 όπου μεσολαβούν Τ-κύτταρα.
CY20061100732T 2000-04-06 2006-06-05 Συστημα μικροβιακης παροχης CY1105216T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19503500P 2000-04-06 2000-04-06
US09/731,375 US8153414B2 (en) 2000-04-06 2000-12-06 Microbial delivery system
PCT/US2000/033121 WO2001066136A2 (en) 2000-04-06 2000-12-06 Microbial delivery system

Publications (1)

Publication Number Publication Date
CY1105216T1 true CY1105216T1 (el) 2010-03-03

Family

ID=26890647

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100732T CY1105216T1 (el) 2000-04-06 2006-06-05 Συστημα μικροβιακης παροχης

Country Status (11)

Country Link
US (6) US8153414B2 (el)
EP (1) EP1272213B1 (el)
JP (3) JP2004527450A (el)
AT (1) ATE319475T1 (el)
AU (2) AU2001219510B2 (el)
CA (1) CA2403292C (el)
CY (1) CY1105216T1 (el)
DE (1) DE60026584T2 (el)
DK (1) DK1272213T3 (el)
ES (1) ES2260078T3 (el)
WO (1) WO2001066136A2 (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6698162B2 (en) * 2000-03-23 2004-03-02 Teikoku Pharma Usa, Inc. Methods of producing a terminally sterilized topical patch preparation
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP1272213B1 (en) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
WO2001076642A1 (en) * 2000-04-07 2001-10-18 The Regents Of The University Of California Synergistic improvements to polynucleotide vaccines
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR101164509B1 (ko) * 2002-12-16 2012-07-10 글로브이뮨 면역 요법으로서의 효모계 백신
US20070231796A1 (en) 2003-09-17 2007-10-04 The Regents Of The University Of California Sensor and method for detection of a target substance
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
KR20070068460A (ko) * 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
JP2009500454A (ja) * 2005-07-11 2009-01-08 グローブイミューン， インコーポレイテッド 標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
WO2007133835A2 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and mehods related thereto
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN104120086A (zh) 2007-02-02 2014-10-29 环球免疫公司 用于生产基于酵母的疫苗的方法
RU2505313C2 (ru) * 2007-03-19 2014-01-27 Глоубиммьюн, Инк. Композиции и способы направленного устранения мутационного ускользания в направленной терапии рака
PT2244734T (pt) 2008-02-01 2016-08-05 Murdoch Childrens Res Inst Método para induzir tolerância a um alérgeno
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
EP2419126B1 (en) 2009-04-17 2018-01-10 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
US20120171230A1 (en) * 2009-07-13 2012-07-05 Vaxgene Corporation Oral vaccines produced and administered using edible micro-organism
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2012109404A1 (en) 2011-02-12 2012-08-16 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection
RU2619850C2 (ru) 2011-03-17 2017-05-18 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
SG10201605265TA (en) 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
BR112014003477B1 (pt) 2011-08-17 2021-11-03 Globeimmune, Inc. Composição imunoterapêutica de muc1 de levedura
US20130216589A1 (en) * 2012-02-17 2013-08-22 Rich Content Biotech INC. Oral vaccine for aquatic animals
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014049604A2 (en) * 2012-09-05 2014-04-03 Amrita Therapeutics Limited A novel biomedical device for cancer therapy
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US9198869B2 (en) 2013-03-14 2015-12-01 Aimmune Therapeutics, Inc. Manufacture of peanut formulations for oral desensitization
EP2976100B1 (en) 2013-03-19 2020-07-01 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
CN106662578B (zh) 2014-04-03 2021-11-12 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン，インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3700552A1 (en) * 2017-10-25 2020-09-02 Allero Therapeutics BV Treatment of immune diseases by administration of antigen-specific formulations
CA3080601A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy
AU2020276213A1 (en) 2019-05-10 2021-10-28 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
CN115209917A (zh) * 2020-02-06 2022-10-18 过敏原有限责任公司 用于检测花生过敏的测定法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588799A (en) * 1897-08-24 Mechanism
US3097141A (en) 1959-02-26 1963-07-09 Kidwell Elizabeth N Wilcox Immunological method
SE337223B (el) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4469677A (en) 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
US4338297A (en) 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
DE3269567D1 (en) 1981-04-29 1986-04-10 Ciba Geigy Ag New devices and kits for immunological analysis
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
CA1338705C (en) 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
SE8205908D0 (sv) 1982-10-18 1982-10-18 Pharmacia Diagnostics Ab Sett att bilda polymerskikt
US4849337A (en) 1983-01-31 1989-07-18 Minnesota Mining And Manufacturing Company Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody
CA1260828A (en) 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
US4579840A (en) 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4696915A (en) 1984-05-25 1987-09-29 Hoffmann-La Roche Inc. Parathymosin alpha
US5026545A (en) 1984-09-17 1991-06-25 Baxter International, Inc. Treatment of allergy and composition therefor
US4658022A (en) 1985-08-08 1987-04-14 Molecular Diagnostics, Inc. Binding of antibody reagents to denatured protein analytes
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5843710A (en) 1987-07-07 1998-12-01 Biotech Australia Pty. Limited And Csiro Vaccines against animal parasitic nematodes
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
AT393137B (de) 1988-10-14 1991-08-26 Biomay Biotech Prod Verfahren zum screenen einer expressions-cdna- klonbank zur auffindung von polynukleotiden
US5061790A (en) 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
JP2787162B2 (ja) 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
US5834246A (en) * 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
US5328991A (en) 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
EP0500785B1 (en) 1989-11-03 2002-04-17 Immulogic Pharmaceutical Corporation A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
EP0514458A1 (en) 1990-01-31 1992-11-25 The Board of Regents for the University of Oklahoma Assays and treatments for autoimmune diseases
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5091318A (en) 1990-04-13 1992-02-25 Abbott Laboratories Binding of allergens to a solid phase
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
WO1992002621A2 (en) 1990-08-08 1992-02-20 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Allergens of alder pollen and applications thereof
AT401180B (de) 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
EP0495064B1 (en) 1990-08-13 2001-07-11 "BIOMAY" Produktions- und Handelsgesellschaft m.b.H. Birch pollen allergen p14 for diagnosis and therapy of allergic diseases
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
KR950008087B1 (ko) 1990-09-17 1995-07-25 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 폴리카보네이트, 그 용도, 그 제조방법 및 정제방법
US5599537A (en) 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
JP3156237B2 (ja) 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
CA2130453A1 (en) * 1992-02-27 1993-09-02 Richard W. F. Le Page Heterologous gene expression in lactococcus, and the expression products threrefrom
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
EP0603992B2 (en) 1992-12-22 2000-12-06 University Of Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
AU5957694A (en) 1992-12-31 1994-08-15 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
ATE162397T1 (de) 1993-02-12 1998-02-15 Mayo Foundation Zusammensetzung aus mikropartikeln in verdichteter phase und verfahren
EP0692031B1 (en) 1993-02-22 2007-04-11 The General Hospital Corporation Heterologous antigens in live cell vaccine strains
JP3451572B2 (ja) 1993-03-04 2003-09-29 アサヒビール株式会社 改変したダニ主要アレルゲン及びその製造方法
US5710126A (en) 1993-03-12 1998-01-20 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
NZ263913A (en) 1993-03-12 1997-10-24 Immulogic Pharma Corp Lol pi protein allergen from ryegrass and related peptides coding sequences, vectors, protein production and use
US6849427B1 (en) 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JP3350794B2 (ja) 1993-09-29 2002-11-25 アサヒビール株式会社 改変したダニ主要アレルゲン
JP2828391B2 (ja) 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US5449669A (en) 1993-11-10 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services IgE-binding epitopes of a major heat-stable crustacean allergen derived from shrimp
US5731157A (en) 1993-12-30 1998-03-24 The Procter And Gamble Company Two-site allergen immunoassay
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH07285875A (ja) 1994-04-19 1995-10-31 Mineo Hayazaki ノミアレルゲンの製造方法および該方法により製造されるノミアレルゲン
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
SE9402089D0 (sv) 1994-06-14 1994-06-14 Rudolf Valenta Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0819763B1 (en) 1995-03-28 2004-11-17 Asahi Breweries, Ltd. Engineered acarid allergen and process for producing the same
US5840307A (en) 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5820880A (en) 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
CA2241918C (en) * 1995-12-29 2008-12-02 University Of Arkansas Peanut allergens and methods
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
SE9604815D0 (sv) * 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
WO1998044096A2 (en) * 1997-03-28 1998-10-08 Cytoclonal Pharmaceutics, Inc. Mycobacterium recombinant vaccines
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
EP0877033B1 (en) 1997-05-08 2007-09-12 Amarnath Maitra A process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
DE19729327C1 (de) * 1997-07-09 1998-10-29 Wieland Electric Gmbh Schutzleiterklemme
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
JP2002501748A (ja) * 1998-01-31 2002-01-22 ユニバーシティ オブ アーカンソー アレルギー反応を減少させるための方法および試薬
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6270723B1 (en) 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
US6086898A (en) * 1998-06-23 2000-07-11 The Board Of Trustees Of The Leland Stanford Junior University Method of converting a Th2-type allergic immune response into a Th1-type immune response
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
JP2000210050A (ja) 1998-11-20 2000-08-02 Asama Kasei Kk 免疫調節活性分解物およびその製造方法並びにそれを用いた食品
WO2000054803A2 (en) * 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
EP1272213B1 (en) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
EP1219300B1 (en) 2000-12-28 2006-12-06 BIOMAY Produktions- und Handels- Aktiengesellschaft Treatment of allergies
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
DE60026584D1 (de) 2006-05-04
ES2260078T3 (es) 2006-11-01
US8153414B2 (en) 2012-04-10
ATE319475T1 (de) 2006-03-15
US20130142817A1 (en) 2013-06-06
US8815251B2 (en) 2014-08-26
JP2012207032A (ja) 2012-10-25
AU1951001A (en) 2001-09-17
WO2001066136A3 (en) 2001-12-27
EP1272213B1 (en) 2006-03-08
US20130243814A1 (en) 2013-09-19
US20030035810A1 (en) 2003-02-20
US20040234548A1 (en) 2004-11-25
AU2001219510B2 (en) 2007-06-14
WO2001066136A2 (en) 2001-09-13
DE60026584T2 (de) 2007-03-08
US20110027298A1 (en) 2011-02-03
JP2004527450A (ja) 2004-09-09
US20040208894A1 (en) 2004-10-21
EP1272213A2 (en) 2003-01-08
CA2403292A1 (en) 2001-09-13
CA2403292C (en) 2011-02-08
DK1272213T3 (da) 2006-07-10
JP2009242427A (ja) 2009-10-22

Similar Documents

Publication Publication Date Title
CY1105216T1 (el) Συστημα μικροβιακης παροχης
Mondoulet et al. Gata3 hypermethylation and Foxp3 hypomethylation are associated with sustained protection and bystander effect following epicutaneous immunotherapy in peanut‐sensitized mice
Tordesillas et al. Immunology of food allergy
Palomares et al. Role of Treg in immune regulation of allergic diseases
Nakamizo et al. Commensal bacteria and cutaneous immunity
Ryan et al. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens
Sambhara et al. Immunosenescence and influenza vaccine efficacy
CY1119074T1 (el) Αγωγη για αλλεργια σε φιστικια
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
Wong et al. Toll‐like receptors and diabetes
ATE433996T1 (de) Humane dr4-antikörper und deren anwendungen
Shiu et al. Dendritic cell function in the host response to Helicobacter pylori infection of the gastric mucosa
CY1115524T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4
Johnson et al. Nanotechnology-based vaccines for allergen-specific immunotherapy: Potentials and challenges of conventional and novel adjuvants under research
Hartl et al. Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a
Hochreiter et al. Prevention of allergen‐specific IgE production and suppression of an established Th2‐type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch‐pollen allergen
ATE466585T1 (de) Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
Chen et al. Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch
Davis et al. TLR3 agonist improves survival to secondary pneumonia in a double injury model
Houri‐Haddad et al. The effect of chronic emotional stress on the humoral immune response to Porphyromonas gingivalis in mice
TR200001948T2 (tr) Mikobakteri vaccaesinden türetilen kompozisyonlar ve bunların kullanımları için metotlar.
Adler Würtzen et al. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity
MY146106A (en) Antiallergic vaccine composition, method for its preparation and use in the treatment of allergic diseases
Johnson-Weaver et al. Adjuvanted immunotherapy approaches for peanut allergy
Saadi et al. Induction of IL-12 from human monocytes after stimulation with Androctonus crassicauda scorpion venom